TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dual Versus Single Shock for Cardioversion of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient or inpatients with atrial fibrillation sent for elective direct current cardioversion (DCCV) with at least 1 of the following risk factors will be included:~  * BMI \>30~ * History of Chronic Obstructive Pulmonary Disease/emphysema/asthma~ * Significant Valvular heart disease (at least moderate regurgitation/stenosis)~ * History of Heart Failure with preserved Ejection Fraction/Heart Failure with reduced Ejection Fraction~ * Cardiomyopathy with ejection fraction \<40%~ * Left atrium anterior-posterio (AP) dimension \>4.5cm~ * Presence of Left ventricular hypertrophy (≥1.1cm septal/posterior wall M-mode) on transthoracic echocardiogram~ * History of sleep apnea~Exclusion Criteria:~* Consent not obtained~* \<18 y.o.~* \>80 y.o.~* Not adequately anti-coagulated~* Patient hemodynamically unstable and DCCV required as an emergent procedure~* Prisoners or pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Single Shock Group (Type: ACTIVE_COMPARATOR): Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only.
- Double Shock Group (Type: ACTIVE_COMPARATOR): Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed adenocarcinoma of the breast and appropriate for treatment with Doxorubicin and Cyclophosphamide.~2. Age \> 18 years and \<45 years.~3. ECOG performance status of 0 to 2.~4. Signed informed consent.~5. Premenopausal: defined as regularly occurring menstrual cycles or serologic estradiol and FSH levels consistent with premenopausal status.~Exclusion Criteria:~1. Patients with distant metastatic disease will be excluded.~2. Pregnancy or breast feeding (women of childbearing potential must have a negative pregnancy test). Women of childbearing potential must be willing to consent to using effective contraception (oral contraceptive pill or implant or barrier method) while on treatment and for a 30 days after taking the last dose of chemotherapy.~3. Male sex will be excluded.~4. Use of agent designed to suppress ovarian function (i.e. LHRH agonist).~5. Use of exogenous estrogen (hormone replacement therapy) will be prohibited with the exception of topical vaginal preparations (as deemed necessary by the treating physician) and oral contraceptives.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to daily self-administer AMG 337 orally as a whole capsule~* Male or female 18 years of age or over.~* Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid tumor (Cohort 2) for which subject has received prior therapy for advanced disease, for which no standard therapy exists, or subject refuses standard therapy~* Tumor MET amplified by protocol-specified centralized testing.~* Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1~* (ECOG) Performance Status of 0, 1 or 2~Exclusion Criteria:~* Known central nervous system metastases~* Candidate for curative surgery or definitive chemoradiation~* Peripheral edema \> grade 1~* Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption~* Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the opinion of the investigator or Amgen physician, if consulted, would not pose a risk to subject safety~* Detectable Hepatitis C virus (indicative of active Hepatitis C)~* Currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatment~* Prior treatment with small molecule inhibitors of the MET pathway.~Other protocol defined inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): AMG 337 Monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Preterm infants with birth weight \< 1250g.~2. Inborn or outborn infants~3. Less than 72 hours of age.~Exclusion Criteria:~1. Congenital malformations.~2. Acute abdomen needing surgical intervention.~3. Severity of illness such that death is likely in the first few days after birth.~4. Inability to get the parental consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Intervention group will receive the glycerin suppository
- Control (Type: NO_INTERVENTION): Normal care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of an Exercise Program on Physical Function After a Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sustained a traumatic spinal cord injury,~2. 16-50 years of age,~3. Able to push a manual wheelchair and arm ergometer,~4. Able to participate in exercise three times per week for 30 minutes,~5. Able to follow English instructions.~Exclusion Criteria:~1. Unstable cardiovascular status (congestive heart failure, uncontrolled hypertension, uncontrolled atrial fibrillation, or left ventricular failure),~2. Significant musculo-skeletal problems (e.g., rheumatoid arthritis) or neurological conditions (e.g., Parkinson's disease) due to conditions other than spinal cord injury,~3. Increased pain with exercise.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* End stage renal disease (ESRD) requiring hemodialysis~* On hemodialysis for ≤ 2 calendar months or scheduled to begin hemodialysis within 1 calendar month~* ≥50 years of age~* Documented Ejection Fraction \> 35% within the previous calendar year~* - If the patient has been hospitalized for a myocardial infarction or heart failure decompensation, the Ejection Fraction measurement must have occurred during the last hospitalization or after discharge~Exclusion Criteria:~* Is receiving or will receive hemodialysis due to acute kidney injury and is not expected to receive subsequent chronic hemodialysis therapy~* Patient has an active ICD~* Patient has a unipolar pacemaker~* Patient has physical or mental conditions preventing him/her from interacting with or wearing a Wearable Cardioverter Defibrillator~* Patient has a chest circumference at the level of the xiphoid of \< 24 inches~* Patient has a chest circumference at the level of the xiphoid of \> 56 inches~* Patient has an advance directive prohibiting resuscitation~* Patient has cancer or other terminal disease (excluding ESRD) with expected survival less than 6 months~* Patient is medically unstable for reasons not specifically related to kidney disease~* Patient is scheduled for live-donor kidney transplantation within 6 calendar months~* Patient is unable to consent

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wearable Cardioverter Defibrillator (Type: EXPERIMENTAL): End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
- Conventional Treatment (Type: NO_INTERVENTION): Conventional Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bleeding Prediction in Patients Following Cardiac Surgery Using Whole Blood Aggregometry and Thromboelastometry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. \> 18 years old~2. Elective cardiac surgery patients~3. Coronary artery disease~4. Aortic valve disease~5. Mitral valve disease~6. Ascendent aorta aneurysm~7. Combine coronary and valve disease~8. Cardiac surgery procedures using cardiopulmonary bypass~Exclusion Criteria:~1. Missing consent~2. Patients with emergent cardiac surgical procedures~3. Patients on antiplatelet therapy other than aspirin or clopidogrel~4. Patients with inaccurate antiplatelet therapy administration documentation~5. Missing data~6. Off-pump procedures~7. Patients younger than 18 years old~8. Patients with severe mental disorders~9. Intrinsic coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients undergoing elective cardiac surgery (Type: None): Patients undergoing elective cardiac surgery will be enrolled in study. Data about antiplatelet therapy ingestion prior to surgery will be included.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Couples with less than or equal to (\<= ) two failed fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) embryo transfer cycles~* Age greater than or equal to (\>=) 18 and \<= 40 years~* Body mass index (BMI): 18-30 kilogram per meter square (kg/m2)~* Normal uterine cavity under ultrasound~* Participant and her husband/partner must have read and signed the Informed Consent form (ICF)~* At least four normally fertilized oocytes (2Pronuclear stage (PN)) in the current cycle~Exclusion Criteria:~* Male with non-ejaculated sperm~* Participants with abnormal, undiagnosed gynecological bleeding or with genitourinary malformations~* Participants with any contraindication to Controlled Ovarian Stimulation (COS) for Assisted Reproductive Technologies (ART) or to gonadotropins~* Planned freeze all cycle (oocytes or embryos)~* Planned preimplantation genetic screening (PGS) or Pre-implantation genetic diagnosis (PGD) cycle~* Concurrent participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- GERI+ Incubator (Type: ACTIVE_COMPARATOR): None
- Conventional incubator (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Metabolic Control in Diabetic Young Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 7 to 11~* Recently diagnosed with T1DM~* Treated at Mount Sinai or at North General Hospital~Exclusion Criteria:~* Children below age 7 and above age 11~* Individual with diminished mental capacity, such that they would not be able to either complete the assessments or comprehend the materials presented in the intervention, will be excluded.~* Individuals without sufficient command of the English language to permit participation (due to the verbal nature of the intervention and the assessment package, and the linguistic limitations of the study team).

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Behavioral: Cognitive Behavior Therapy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have biopsy-proven solid tumor that is eligible for elective surgical resection, disease does not require immediate therapy, and there is NO approved/ standard therapy available that is shown to prolong overall survival.~2. ECOG performance status of 0 or 1.~3. Must have a tumor lesion that is amenable to biopsy, and willing to undergo biopsy.~4. Willing to provide tissue and blood samples for research.~Exclusion Criteria:~1. The following solid tumors are NOT eligible: Primary brain tumor, Ocular melanoma, Head and neck cancer, Breast cancer, Prostate cancer, Testicular cancer, and Stage III rectal cancer.~2. Any active malignancy within 3 years prior, except: Adequately treated basal cell or squamous cell skin cancer, or early stage cancers (carcinoma in situ or stage 1) treated with curative intent.~3. Any uncontrolled intercurrent illness, including but not limited to: Symptomatic congestive heart failure, Unstable angina pectoris or coronary angioplasty or stenting within 6 months prior to enrollment, Cardiac arrhythmia, Psychiatric illness or social situations that would limit compliance with study requirements, or Ongoing or active infection.~4. Any known sensitivity to or history of allergic reaction to compounds of similar chemical or biological composition of study drug(s).~5. Unwilling or unable to follow the study schedule.~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Sub-Protocol A (Type: EXPERIMENTAL): Epacadostat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Structural Analysis of Human Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects, male or female , between the ages of 18 to 65 years of age, who will be having surgery to remove excess skin from the abdominal area by surgeons in the Department of Plastic \& Reconstructive Surgery~Exclusion Criteria:~* Subjects younger then 18 years of age or older than 65 years of age, and are not having excxess skin surgically removed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Food Reward in Cachexia Induced by Acute or Chronic Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* For cachectic patients: weight loss exceeds 5% of total body weight over the past 6 months, or \>2% when body mass index is \<20 kg/m2~* For non-cachectic patients: no weight loss of ≥5% during the last 6 months~* Non-small cell lung cancer or gastro-intestinal cancer, pathology proven or diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria~Exclusion Criteria:~* Contra-indications for fMRI examination (operation to your head or brain in the past; implanted electronic devices, for instance a pacemaker, neurostimulator, cochlear or hearing implant; insulin pump under your skin; Pregnant subjects, claustrophobia; pregnancy; metal parts in your body (except from teeth filling and connectors): implants; brain vessel clamps, prostheses, intra-uterine device, metal splinter in the eye, metal braces or other metal objects, permanent eye make-up)~* Psychiatric or other disorders likely to impact on informed consent~* Presence of brain metastasis (screening is not mandatory)~* Medical history of cerebrovascular accident, brain tumour, brain metastasis~* Previous radiotherapy to brain, both stereotactic and whole brain radiotherapy~* Memory problems~* Current use of tube feeding or parental nutrition~* Patients with an active second malignancy~* Patients unable to lie still for 2 hours~* Unable to complete the cognitive task~* Pre-existing swallowing difficulties~* Allergy to gluten-, milk- or wheat products~* Self-reported hyperthyroidism~* Self-reported diabetes mellitus~* Current use of appetite stimulant medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cachectic cancer patients (Type: None): Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
- Non-cachectic cancer patients (Type: None): Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
- Cachectic COPD patients (Type: None): Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
- Non-cachectic COPD patients (Type: None): Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The AVATAR Trial: Applying VAcuum To Accomplish Reduced Wound Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 0-17 years old~* any emergency or elective laparoscopic procedure requiring an umbilical port~Exclusion Criteria:~* immunocompromise (acquired or iatrogenic)~* malignancy~* requiring blood transfusion within 6 weeks of surgery~* history of splenectomy~* significant comorbid conditions, such as severe cardiopulmonary disease~* presence of any chronic abdominal wound, cellulitis, or enterocutaneous fistula~* pregnancy~* smoker~* BMI \> 30~* inability to attend follow up~* language barrier

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Vacuum (Type: EXPERIMENTAL): the group of patients assigned to application of vacuum to the wound dressing
- Control (Type: ACTIVE_COMPARATOR): The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues